Proactive Investors - Run By Investors For Investors

OptiBiotix Health sees revenues build as agreements turn into commercial deals

Per Rehne, commercial director at OptiBiotix Health plc (LON:OPTI),  gives Proactive's Andrew Scott a commercial update for their probiotic division and looks ahead to the launch of their online platform which is expected in the coming weeks.

''In just over a year now we've announced 19 deals and 12 of those deals have been related to LPLDL® covering manufacturing partners ... and sales and distribution partners''.

''Sales are continuing and ongoing .. over the summer we made some deliveries to an unnamed customer in France ... we're starting to see repeat business which is always good, agreements are turning into commercial revenues''.

''We do expect the revenues will continue to build especially into the second half of this year and into 2019''.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use